Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Osteoporosis
Interventions
DRUG

Prolia

Partcipants will receive subcutaneous (SC) injections of Prolia Q6M.

Trial Locations (16)

100034

RECRUITING

Peking University First Hospital, Beijing

100035

RECRUITING

Beijing Jishuitan Hospital, Beijing

150001

RECRUITING

The Fourth Hospital of Harbin Medical University, Harbin

200233

RECRUITING

Shanghai Sixth Peoples Hospital, Shanghai

210011

RECRUITING

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

215300

RECRUITING

The First Peoples Hospital of Kunshan, Suzhou

221002

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

221009

RECRUITING

Xuzhou Central Hospital, Xuzhou

223300

RECRUITING

Huaian First Peoples Hospital, Huaian

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

330038

RECRUITING

Jiangxi Provincial Peoples Hospital, Nanchang

337000

RECRUITING

Pingxiang Peoples Hospital, Pingxiang

400042

RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

510120

RECRUITING

Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou

510515

RECRUITING

Nanfang Hospital Southern Medical University, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY